[go: up one dir, main page]

BRPI0509923A - processo para formação de cálcio de atorvastatina amorfa - Google Patents

processo para formação de cálcio de atorvastatina amorfa

Info

Publication number
BRPI0509923A
BRPI0509923A BRPI0509923-4A BRPI0509923A BRPI0509923A BR PI0509923 A BRPI0509923 A BR PI0509923A BR PI0509923 A BRPI0509923 A BR PI0509923A BR PI0509923 A BRPI0509923 A BR PI0509923A
Authority
BR
Brazil
Prior art keywords
amorphous atorvastatin
formation process
atorvastatin calcium
atorvastatin
calcium formation
Prior art date
Application number
BRPI0509923-4A
Other languages
English (en)
Inventor
Peter Robert Rose
Jason Albert Leonard
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509923(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0509923A publication Critical patent/BRPI0509923A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCESSO PARA FORMAçãO DE CáLCIO DE ATORVASTATINA AMORFA. Formação de atorvastatina amorfa compreende as etapas de dissolução de cálcio de atorvastatina em um solvente para formar uma solução, seguido pela adição da solução a uma mistura compreendendo um não solvente e um solvente hidroxílico para proporcionar atorvastatina amorfa.
BRPI0509923-4A 2004-04-16 2005-04-04 processo para formação de cálcio de atorvastatina amorfa BRPI0509923A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56294804P 2004-04-16 2004-04-16
PCT/IB2005/000884 WO2005100313A1 (en) 2004-04-16 2005-04-04 Process for forming amorphous atorvastatin calcium

Publications (1)

Publication Number Publication Date
BRPI0509923A true BRPI0509923A (pt) 2007-09-18

Family

ID=34963002

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509923-4A BRPI0509923A (pt) 2004-04-16 2005-04-04 processo para formação de cálcio de atorvastatina amorfa

Country Status (16)

Country Link
US (1) US20070225353A1 (pt)
EP (1) EP1742910A1 (pt)
JP (2) JP2007532622A (pt)
KR (1) KR100829268B1 (pt)
CN (1) CN1960972A (pt)
AR (1) AR048756A1 (pt)
AU (1) AU2005232959A1 (pt)
BR (1) BRPI0509923A (pt)
CA (1) CA2562844A1 (pt)
IL (1) IL178574A0 (pt)
MX (1) MXPA06011987A (pt)
NO (1) NO20065229L (pt)
RU (1) RU2330840C1 (pt)
TW (1) TW200538111A (pt)
WO (1) WO2005100313A1 (pt)
ZA (1) ZA200608632B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070054730A (ko) * 2004-10-18 2007-05-29 테바 파마슈티컬 인더스트리즈 리미티드 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는방법
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
JP2009517459A (ja) * 2005-11-29 2009-04-30 バイオコン・リミテッド ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸マグネシウム塩（２：１）の多形
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
CN101538237B (zh) * 2008-05-30 2011-04-06 天津和美生物技术有限公司 阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
DE69324504T2 (de) * 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL128864A (en) * 1995-07-17 2007-10-31 Warner Lambert Co Atorostatin II form crystals and its hydrates, methods of preparation and pharmaceutical preparations containing it
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
DK0915866T3 (da) * 1996-07-29 2002-06-10 Warner Lambert Co Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
US6433213B1 (en) * 1997-12-19 2002-08-13 Warner-Lambert Company Process for the synthesis of 1,3-diols
IN191236B (pt) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
US6605759B1 (en) * 2000-12-22 2003-08-12 Pioneer Hi-Bred International, Inc. Soybean variety 95B34
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium

Also Published As

Publication number Publication date
AU2005232959A1 (en) 2005-10-27
JP2008255117A (ja) 2008-10-23
AR048756A1 (es) 2006-05-24
CA2562844A1 (en) 2005-10-27
KR20060133061A (ko) 2006-12-22
NO20065229L (no) 2006-11-14
ZA200608632B (en) 2008-06-25
RU2330840C1 (ru) 2008-08-10
US20070225353A1 (en) 2007-09-27
CN1960972A (zh) 2007-05-09
RU2006136902A (ru) 2008-04-27
EP1742910A1 (en) 2007-01-17
TW200538111A (en) 2005-12-01
MXPA06011987A (es) 2007-01-16
JP2007532622A (ja) 2007-11-15
KR100829268B1 (ko) 2008-05-13
WO2005100313A1 (en) 2005-10-27
IL178574A0 (en) 2007-02-11

Similar Documents

Publication Publication Date Title
BRPI0810011A2 (pt) Microorganismo, e, métodos para produzir uma substância ácida tendo um grupo carboxila, e para produzir um polímero contendo ácido succínico
BRPI0706947B8 (pt) método de preparação de uma composição de micropartícula
ATE536192T1 (de) Vernetzte hyaluronsäure und kollagen und ihre verwendungen
CL2009001081A1 (es) Procedimiento para producir un vehiculo en forma de particulas que comprende disolver polibutilcianoacrilado en un disolvente organico para formar una solucion polimerica, anadir una solucion acuosa, mezclar y obtener el vehiculo en forma de particulas; composicion farmaceutica que comprende dicho vehiculo.
BRPI0512347A (pt) preparação da pregabalina e compostos relacionados
EP1698937A3 (en) Positive resist composition and pattern-forming method using the same
BRPI0803374A2 (pt) compostos polihidróxi como agentes de extinção de polimerização
BRPI0809696A8 (pt) Catalisador de base biológica para retardar processos de desenvolvimento de plantas
BR112012026357A2 (pt) processo para a preparação de pirrolinas a partir de gama-nitrocetonas. uso das gama-intracetonas como pesticidas
BR112015001655A2 (pt) método para purificar pelo menos uma saponina em uma solução, componente de produto de saponina qs-21 purificada, e, composição imunogênica
BR112012033195A2 (pt) método de dissolver materiais lignocelulósicos.
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
BRPI0908833A2 (pt) Composição polimérica elastomérica biodegradável, processo para preparar uma composição polimérica, e, uso da composição polimérica.
BRPI0411313A (pt) processo para formar atorvastatina amorfa
BRPI1010546B8 (pt) processo para produzir composto, método para isolar e purificar cristais de solvato do composto, e, uso do composto
TW200745758A (en) Base soluble polymers for photoresist compositions
BRPI0509923A (pt) processo para formação de cálcio de atorvastatina amorfa
BR112013018557A2 (pt) método de tratamento de infecções
BRPI0820888B8 (pt) Copolímero de metacrilato de aminoalquila e, seu uso e seu método de produção, e formulação farmacêutica
AR056395A1 (es) Composicion que comprende asfalto, copolimero de etileno y azufre
CL2010000981A1 (es) Metodo para preparar microparticulas con droga que comprende disolver un polimero biodegradable en solvente organico, disolver o dispersar una droga en la solucion, mezclar la fase de solvente droga-polimero con una suspension acuosa de gel inorganico y evaporar el solvente, recuperando las microparticulas agregando acido a la dispersion.
AR051144A1 (es) Procedimiento para formar atorvastatina amorfa
DE602006017724D1 (de) Salicylsäurederivate
EP2057899A3 (en) Method for making cyclopropene inclusion complex
EP1975713A3 (en) Positive resist composition and pattern forming method using the same

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.